So one of the, the areas of of interest within platinum resistant ovarian cancer is obviously how can we find combinatorial agents uh to help increase the efficacy of of checkpoint inhibitors and other immune therapies. And obviously one of the interesting uh agents to try to combine with that are things that ramp up and turn on the immune system like uh cytokines and specifically IL 2. Uh, I know many people are very worried of IL-2, given its history and it's, uh, fairly severe side effect profile. Uh, however, many companies have been looking at and, and how we can re-engineer IL-2 to perhaps focus on the positive sides, which are the activation of uh CD4 positive T cells and CDA T cells without the negative implication of Uh, activating and binding to vascular endothelial cells as well as to regulatory cells, and, and perhaps turn the immune system on significantly in combination with our immune checkpoint inhibitors to see if we can enhance the response of either of these two agents, uh, either of these two single agents going forward. Uh, nimbaleukin is the most advanced of these, uh, technologies currently in clinical development, and it's a recombinant IL-2 that has, uh, gotten rid of the high the high affinity binding alpha subunit, so that it preferentially binds, uh, the other two subunits of the interleukin 2 receptor and does not activate two regulatory cells or vascular endothelial cells, which hopefully limits its its ability to cause significant side effects that we saw with high doidal2 historically, as well as Uh, remodeling the tumor microenvironment so that is more conducive to the checkpoint inhibition. So one of the, the areas of of interest within platinum resistant ovarian cancer is obviously how can we find combinatorial agents uh to help increase the efficacy of of checkpoint inhibitors and other immune therapies. And obviously one of the interesting uh agents to try to combine with that are things that ramp up and turn on the immune system like uh cytokines and specifically IL 2. Uh, I know many people are very worried of IL-2, given its history and it's, uh, fairly severe side effect profile. Uh, however, many companies have been looking at and, and how we can re-engineer IL-2 to perhaps focus on the positive sides, which are the activation of uh CD4 positive T cells and CDA T cells without the negative implication of Uh, activating and binding to vascular endothelial cells as well as to regulatory cells, and, and perhaps turn the immune system on significantly in combination with our immune checkpoint inhibitors to see if we can enhance the response of either of these two agents, uh either of these two single agents going forward. Uh, nimbaleukin is the most advanced of these, uh, technologies currently in clinical development, and it's a recombinant IL-2 that has, uh, gotten rid of the high the high affinity binding alpha subunit, so that it preferentially binds, uh, the other two subunits of the interleukin 2 receptor and does not activate two regulatory cells or vascular endothelial cells, which hopefully limits its its ability to cause significant side effects that we saw with high doidal to historically, as well as Uh, remodeling the tumor microenvironments so that is more conducive to the checkpoint innovation.
Presenter
